Medgenics reports plans to price public offering of its common shares

Maxim Group is the bookrunner; offering has 45-day greenshoe option

By Devika Patel

Knoxville, Tenn., Feb. 7 - Medgenics Inc. will price a public offering of common stock and warrants with a 45-day greenshoe option, according to a preliminary prospectus supplement filed Thursday with the Securities and Exchange Commission.

Maxim Group LLC is the bookrunner.

Proceeds will be used for product development activities, including clinical trials, development and investigation of new applications, patent maintenance fees and intellectual property support, and for working capital and other general corporate purposes, which may include the acquisition or licensing of complementary technologies, products or business.

The medical technology and therapeutics company is based in San Francisco.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.